NASDAQ: TRAW · Life Sciences · 3 alerts · CIK 1130598
Share price
$0.2600Close, Nov 16
Market cap
$4M
Shares outstanding
15.37MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Traws Pharma, Inc. filings on SEC EDGAR ↗
Traws Pharma announced final Phase 2a results for Ratutrelvir, showing symptom resolution comparable to PAXLOVID with no viral rebound and fewer treatment-related adverse events in COVID-19 patients. The company also completed a bridging study for Tivoxavir Marboxil (TXM), supporting its potential as a once-monthly influenza prophylactic agent.
Traws Pharma entered into a common stock purchase agreement with Roth Principal Investments for an equity line of credit of up to $50 million. The company has the right, but not the obligation, to sell shares to Roth over a 36-month period following the effectiveness of a registration statement. This facility provides the company with flexible access to capital to fund operations at its sole discretion.